At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine – Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only). Nanosphere is collaborating with AnalizaDx – which has developed a proprietary platform to screen for protein biomarkers in serum and other biological fluids – on development of next-generation PSA tests for prostate cancer.
Data presented for blood serum showed that at a sensitivity of 100%, the specificity was 76%, with a negative predictive value of 100% (ruling out patients who do not have prostate cancer) and a positive predictive value of 84% (likelihood that a patient ruled in would have cancer based on biopsy). The use of the Nanosphere Verisens™ ultra-sensitive PSA assay achieved sensitivity and specificity required for prostate cancer diagnosis, that is not possible with existing commercial assays.
In addition to Case Western, the academic investigators were from Cleveland Clinic, the Veterans Administration Healthcare System in Boston, and the National Cancer Institute.
Source: Case Western Reserve University School of Medicine